MedTrace Logo

Aldosterone Blockade to Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension

NCT00980031 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-03-28

No results posted yet for this study

Summary

The goal of this project is to investigate the effects that the addition of aldosterone blockade with eplerenone will have on the progression of diastolic dysfunction in patients with controlled essential hypertension.

Conditions

  • Myocardial Remodeling

Interventions

DRUG

Eplerenone

25mg PO daily (QD)for 6 months

DRUG

Lactose Tablet

Lactose tablet

Sponsors & Collaborators

  • Creighton University

    lead OTHER

Principal Investigators

  • M Jeff Holmberg, MD, PhD · Creighton Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00980031 on ClinicalTrials.gov